Privi Speciality Chemicals Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Strong quarter, margin-led beat: Revenue grew ~22% YoY to ~₹568 crores, but EBITDA jumped 45% YoY to ₹141 crores (24.8% margin) as continuous-plant efficiencies lifted profitability even while prices fell.
• The 5,000-1,000 vision is now the organizing story: Management framed the amalgamation, capacity expansion, and biotech IP pipeline around reaching ₹5,000 crores revenue and ₹1,000 crore EBITDA in 3-5 years.
• Efficiency, not pricing, is the margin engine: Converting batch plants to continuous processes augmented capacity, cut labor, and improved automation, driving margin expansion despite lower year-on-year prices.
• Management is guarding its secrets tightly: The company declined to break out volume vs. value growth, individual product contributions, or Colgate-product economics, calling them proprietary.
• What to watch next quarter: Whether Phase 1 capacity expansion starts delivering the promised volume ramp from Q2/Q3, and any concrete patent filings from the biotech IP that management says is imminent.

Margin Structure & Profitability Drivers

• Gross margin expansion: Manufacturing specialty products from by-product streams (Galaxmusk, CST by-products) that were previously sold at lower prices, now converted to value-added products like 1,4-Cineol, 1,8-Cineol, Terpinen-4-ol, Limonene, and DDTO.
• EBITDA conversion lag: Only about 3% of the ~7% YoY gross margin expansion converted to EBITDA margin expansion. Utility expense savings added another 100-200 bps to EBITDA margin. Last year's elevated selling and distribution expenses (US port stoppages forcing extra shipments) should normalize over a larger base going forward.
• RMC outlook: Raw material costs are expected to remain at current levels (53-55% of revenue) for the next couple of years.
• No single-product dependency: Management stated no individual product contributed disproportionately to margins; the improvement is a culmination of all factors together.
• Prionyl competitive position: Capacity has been increased. A unique green process vs. competitors, economies of scale from being located within Mahad (lower cost), and best-in-class quality help withstand competition.

Babani: "Price increase, rather I would say we are lower on price compared to last year, but yet better profitability, to be honest."

Capacity Expansion & Growth Pipeline

• Phase 1 on track: Entire Phase 1 expansion expected to be completed by this year-end, enabling 20% growth even in the next couple of years. Some expansions have already started giving results or will start from Q2, more so from Q3.
• Phase 2 in planning: Management is parallelly looking at Phase 2 expansion, expecting to get environmental and other clearances from around Q2/Q3 of this year. This will enable 20%+ growth for the next 3-5 years to achieve the 5,000-1,000 vision.
• Continuous plant conversion: Converting batch plants to continuous processes has augmented capacity, improved automation, reduced labor, and increased production. This initiative has been ongoing for the last ~9 months and is expected to continue delivering capacity gains.
• CAPEX funding: Mix of internal accrual and bank debt. Management noted equity is expensive. The CAPEX to achieve the 5K-1K number is spread over the next 2-3 years.
• Super specialty aroma chemicals: Several developed successfully at lab and pilot levels; these will propel future growth after the current capacity expansion is complete.

Babani: "In short, we have converted our plants into continuous plants and we see capacity augmentation because of that effect. And in fact, if you see our margins improvement is also because of that."

Amalgamation & Biotech IP

• Scheme of amalgamation: Privi Fine Sciences and Privi Biotechnologies are being merged into Privi Specialty Chemicals to simplify the corporate structure, enhance efficiency, and unlock growth opportunities.
• Biotech IP milestone: 10 years of effort in Privi Biotechnologies has generated significant intellectual property, expected to convert into patents in the next couple of months. Management believes this could create intangible wealth and pave the way for more products or even franchising technologies worldwide.
• Privi Fine Sciences rationale: The merger was timed because products at Lote and Gujarat are at a stage where they can be capitalized. Some products will be made for the first time via a renewable route and would be "game changing."
• Cyclopentanol: A key product being worked on at Privi Fine Sciences, currently available only from petroleum sources, will be made from a renewable source. Applications span aroma chemicals, pharma industries, and the electronic chip industry.

Patil: "Some of these products would be made first time by the route that we are making which is a renewable route and they would be game changing kind of products and we have advanced substantially in those areas."

Joint Venture & New Products

• JV status: The JV is yet to break even and remains in a nascent stage. Protocols for supplying fine products are very severe. Management expects the JV to do more than break even this year, with growth contemplated.
• JV expansion plans: Currently only one expansion done; planning three more (1.1, 1.5, and 2). Management has requested lower-priced debt and a rework of existing debt. Long-term prospects are "par excellence," though the turnover ratio is currently low compared to the size of the investment.
• Anethole (Colgate product): On track; management expects to begin selling it going forward very shortly. Details on quantity, revenue, and margins were not disclosed.
• Pharma grade camphor: Various studies ongoing; management believes it should "click around" shortly, though no specific timeline was provided. Domestic demand is currently absorbing all production, so overseas market entry waits on feasibility studies.

Babani: "Long term prospects are par excellence. At the moment, we do face challenges because of, it is a huge, huge project and the turnover ratio is pretty low compared to the size of the investment."

Demand, Tariffs & Working Capital

• Demand outlook: Extremely positive; 70%+ of business is contracted. Products are essential FMCG inputs (soap, toothpaste, deodorant), so demand is stable regardless of economic conditions. Transformation in consumer demand in operating regions and nearby countries is expected to drive sustained growth.
• US tariff impact: Limited impact expected on margins. The US is only 7% of revenue. Any increase will be shared: some borne by customers, some by F&F partners, and some by Privi.
• Working capital target: Management expressed a zeal to bring net working capital days down to 120-125 days.
• Q1 seasonality: Historically Q1 is the lowest quarter; revenue and quantum increase from Q2 onwards.

People & Governance

• Professional management transition: Management is grooming a team of 15 professionals below age 40 to convert the organization into a totally professionally managed one in the next 3-5 years. Two colleagues are being sent to Harvard for training.
• Promoter share sale: Mr. Rao (over 80) sold a fraction (3.5% to 4%) to capitalize on his efforts and commitments to children and family.
• Stock split consideration: Management is thinking about a stock split to increase liquidity and overall participation, though no timeline was committed.
• EcoVadis Platinum Rating: Privi earned a platinum rating, placing it in the top 1% globally for ESG performance.

Babani: "We are grooming a team which will convert this into a totally professionally managed organization in the next three to five years max. And till then, I'm also not going to get old, I'm getting younger, but by energy, I don't know how, God gives energy when you plan right."

Guidance & Commitments

Key Metrics